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Vascular endothelial growth factor receptor-1 (VEGFR-1, also
known as Flt-1) is involved in complex biological processes often
associated to severepathological conditions like cancer, inflamma-
tion,andmetastasis formation.Consequently, thesearchforantag-
onists of Flt-1 has recently gained a growing interest. Here we
report the identificationofa tetrameric tripeptide fromacombina-
torial peptide library built using non-natural amino acids, which
binds Flt-1 and inhibits in vitro its interaction with placental
growth factor (PlGF) and vascular endothelial growth factor
(VEGF) A andB (IC50 10M). The peptide is stable in serum for
7 days and prevents both Flt-1 phosphorylation and the capillary-
like tube formation of human primary endothelial cells stimulated
by PlGF or VEGF-A. Conversely, the identified peptide does not
interfere in VEGF-induced VEGFR-2 activation. In vivo, this pep-
tide inhibits VEGF-A- and PlGF-induced neoangiogenesis in the
chicken embryo chorioallantoic membrane assay. In contrast, in
the cornea, where avascularity is maintained by high levels of
expression of the soluble form of Flt-1 receptor (sFlt-1) that pre-
vents the VEGF-A activity, the peptide is able to stimulate corneal
mouse neovascularization in physiological condition, as reported
previously for others neutralizing anti-Flt-1 molecules. This tet-
rameric tripeptide represents a new, promising compound for
therapeutic approaches in pathologieswhere Flt-1 activation plays
a crucial role.
A complicated tuning of several growth factor families and
related receptors regulates the formation of new vessels (1).
Among these players, the activation of two vascular endothelial
growth factor (VEGF)6 receptors, Flt-1 and VEGF receptor 2
(Flk-1 in mouse, KDR in human), represents a crucial event in
both physiological and pathological angiogenesis (2–4). Three
members of the VEGF family involved in angiogenesis bind and
activate VEGF receptors; VEGF-A binds both Flt-1 and KDR
receptors, whereas two other VEGF family members, VEGF-B
and placental growth factor (PlGF), specifically bind Flt-1. The
activity of VEGF-A is crucial both in physiological and in path-
ological angiogenesis, whereas that of PlGF and VEGF-B
appears to be restricted to pathological conditions (5, 6).
Phenotype analysis of “knock out”mice and in vivo biochem-
ical interaction studies strongly suggest that the inhibition of
Flt-1 activity constitutes an alternative target for therapeutic
modulation of angiogenesis as well as inflammatory disorders
andmetastatic process (7, 8).Plgfnullmice (9),Vegf-Bnullmice
(10), and mice engineered to express a truncated form of Flt-1
lacking the tyrosine kinase domain (11) are borne atMendelian
frequency and are healthy and fertile. However, pathological
angiogenesis in the adult is impaired in all threemousemodels.
Moreover, Flt-1 blockade by neutralizing anti-Flt-1 mono-
clonal antibody (mAb) strongly reduces the neovascularization
in tumors as well as in models of ischemic retinopathy and
age-related macular degeneration (9, 12–14). Recently it has
been reported that neutralizingmAb anti-PlGF is able to inhibit
tumor angiogenesis with an efficacy comparable with that
observed blocking VEGF/Flk-1 pathway (15).
In contrast to KDR, which is predominantly expressed by
endothelial cells (ECs), expression of Flt-1 has been detected
and functionally demonstrated also in smoothmuscle cells (16),
in monocyte-macrophage cells (17), and in bonemarrow stem/
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progenitor-derived cells (12). The activation of Flt-1 is not only
crucial for ECs stimulation during the neoangiogenesis process
(18, 19) but also plays a fundamental role in the stabilization of
neovessels through the recruitment of smooth muscle cells
(16), in the recruitment and differentiation of monocyte-mac-
rophage cells (17, 20–22) and, ultimately, in the reconstitution
of hematopoiesis promoting the recruitment of Flt-1-positive
cells from bone marrowmicroenvironment (23). Furthermore,
Flt-1 activation is decisive in the recruitment of bone marrow-
derived endothelial cells and hematopoietic precursors in
tumor angiogenesis (12) as well as in inflammatory disorders
(22).More recently, it has been shown that Flt-1-positive hema-
topoietic bone marrow progenitors are involved in the estab-
lishment of premetastatic niche and that an anti-Flt-1 mAb
completely prevents metastatic process (24).
Flt-1 receptor also exists as an alternatively spliced soluble
form (sFlt-1) (25) that represents one of the most potent phys-
iological inhibitors of VEGFs activity. Indeed, it is expressed
during embryonic development, where it regulates the avail-
ability of VEGF and, as recently reported, in the adults, it plays
a pivotal role to maintain corneal avascularity (26).
Collectively, these data strongly indicate Flt-1 as an ideal target
for fighting a number ofmajor diseases (7). In the effort to identify
new molecules able to selectively bind Flt-1 and neutralize its
activity, we screened a random combinatorial tetrameric tripep-
tide library built using non-natural amino acids, using a competi-
tive ELISA-based assay (27). The peptidemixtures composing the
librarywere utilized as competitors of the PlGF/Flt-1 binding, and
the most active component was isolated following an iterative
process (28, 29). The biological activity of the selected peptide has
then been assessed in several in vitro and in vivo assays demon-
strating that it is a highly stable and selective Flt-1 binder able to
suppress the receptor activation.
EXPERIMENTAL PROCEDURES
Synthesis of Combinatorial Tetrameric Tripeptide Library
and Analogues of 4-23-5 Peptide—The peptide library was pre-
pared using all commercially available amino acids and resins
purchased from Chem-Impex International (Wood Dale, IL)
and from Novabiochem (Laufelfingen, CH). As 30 different
blocks were utilized (supplemental Table S1), a theoretical
number of 27,000 peptides was generated, split in 30 separate
pools of 900 peptides each. All residues were 9-fluorenylme-
thoxycarbonyl (Fmoc)-derivatized (99%) and were utilized
without any further purification. Amino acids in the D configu-
ration and others bearing trifluoroacetic acid-stable side chain
protections were chosen to increase the library chemical diver-
sity and, at the same time, to introduce resistance to enzyme
degradation (30) for in vitro and in vivo applications. The
library was chemically synthesized following the Fmoc meth-
odology (31), and sequence randomization was achieved apply-
ing the portioning-mixing process as reported elsewhere (28)
(see also the supplemental Experimental Procedures). Other
molecules, such as the monomeric, dimeric, and trimeric trip-
eptide variants, as well as the Ala-scanning peptides (where the
monomers were systematically changed to alanine), were sim-
ilarly prepared using suitable protecting groups. The cyclic
dimeric variant was prepared as described elsewhere (29).
Iterative Deconvolution of Tetrameric Tripeptide Library—
Recombinant PlGF, VEGF-A, VEGF-B, VEGFR-1/Fc chimera,
VEGFR-2/Fc chimera of human and mouse origin, and normal
or biotinylated antibodies anti-PlGF, anti-VEGF-A, and anti-
VEGF-B were purchased from R&D Systems (Minneapolis,
MN). At every step of the deconvolution process, peptide pools
were tested with a molar excess of 1,000-fold (calculated on
each single peptide) over PlGF (1.3  1010 M). Following the
identification of active pools, dose-dependent inhibition exper-
iments using 500-, 1,000-, 1,500-, and 2,000-fold excess were
performed to confirm the inhibitory capacity. The first active
pool identified was the 4-X-X (X indicates randomized posi-
tions) where “4” identified the amino acid D-glutamic acid
(D-Glu, supplemental Table S1). This pool was resynthesized in
30 subpools each composed of 30 peptides and submitted to the
second screening round that allowed the identification of the
subpool 23 (4-23-X). The number “23” identified the amino
acid L-cysteine(S-benzyl) (supplemental Table S1). Finally, the
30 single peptides composing the 4-23-X pool were synthesized
and submitted to the final screening. The peptide 4-23-5, where
the number “5” identified the amino acid L-cyclohexylalanine
(supplemental Table S1), was the unique molecule showing
inhibitory activity.
ELISA-based Assays—The competitive ELISA-based assay
(27) for the screening of the peptide library and for dose-de-
pendent experiments was performed by coating on 96-well
plates a recombinant form of Fc/Flt-1 at 0.5 g/ml, 100 l/well
(the same volume was used for all subsequent steps), 16 h at
room temperature. The plate was then blocked for 3 h at room
temperature with 1% bovine serum albumin (BSA), and a
recombinant form of PlGF at 5 ng/ml concentration in PBS
containing 0.1% BSA, 5 mM EDTA, 0.004% Tween 20 (PBET)
was added and incubated for 1 h at 37 °C followedby 1h at room
temperature. A biotinylated anti-human PlGF polyclonal anti-
body diluted in PBET at 300 ng/ml was added to the wells and
incubated for 1 h at 37 °C followed by 1 h at room temperature.
A solution containing an avidin and biotinylated horseradish
peroxidase macromolecular complex was prepared as sug-
gested by the manufacturer (Vectastain elite ABC kit, Vector
Laboratories, Burlingame, CA) and added to thewells and incu-
bated for 1 h at room temperature followed by the horseradish
peroxidase substrate composed of 1mg/ml ortho-phenylenedi-
amine in 50mMcitrate phosphate buffer, pH 5, 0.006% ofH2O2,
incubated for 40 min in the dark at room temperature. The
reactionwas blocked by adding 30l/well of 4 NH2SO4, and the
absorbance was measured at 490 nm on a microplate reader
(BenchMark, Bio-Rad). Peptide pools or single peptides dis-
solved in DMSO were properly diluted and added to the wells
along with ligand. For dose-dependent experiments performed
withVEGF-AandVEGF-B, 10 ng/ml recombinant proteins and
500 ng/ml polyclonal antibody, anti-human VEGF-A or anti-
human VEGF-B, were used. 4-23-5 and control peptides were
used at concentrations ranging between 1.56 and 50.0 M.
Using the same ELISA-based assay, the inhibitory capacities of
alanine-scan peptides and structurally related analogues (sup-
plemental Table S3) were investigated in both PlGF and VEGF
interaction with Flt-1 receptor. Analogues were used at 50 M,
whereas the 4-23-5 peptidewas used at 12.5M.To evaluate the
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binding of the 4-23-5 peptide to Flt-1 receptor, the peptide or
the negative controls were coated at 20 M. for 16 h at 4 °C. A
recombinant form of extracellular domains of human and
mouse Flt-1 receptors fused to human Fc in PBETwas added to
the wells and incubated for 1 h at 37 °C followed by 30 min at
room temperature. Goat anti-human Fc antibody (Jackson
ImmunoResearch, West Grove, PA) and the secondary donkey
anti-goat hypoxanthine-guanine phosphoribosyltransferase
antibody (Santa Cruz Biotechnology, Santa Cruz, CA), both at
1:1000 dilution, were added and incubated for 1 h at room tem-
perature. Finally, plates were developed as described above. To
evaluate the binding of 4-23-5 to VEGFR-2, recombinant
human Fc/KDR andmouse Fc/Flk-1 were used. To evaluate the
ability of PlGF and VEGF-A to compete the interaction of Flt-1
with the synthetic ligand, 4-23-5 was coated at 20 M, and the
human Fc/Flt-1 receptor was used at a fixed concentration (125
pM). The dose-dependent competition was performed using
PlGF and VEGF-A at concentrations ranging between 0.05 and
6.25 nM.
Stability Assay—The selected 4-23-5 peptide was dissolved
in neat DMSO at a 10 mg/ml concentration. The sample was
then serially diluted in PBS, pH 7.3, containing 10% fetal calf
serum to obtain 100g/ml solutions and incubated at 37 °C for
168 h. 10-l aliquots (1.0 g of total peptide) were removed
after every hour within the first 12 h and subsequently at 24, 72,
120, and 168 h. Samples were immediately centrifuged for 5
min at 14,000 rpm and analyzed by reverse phase-HPLC after
discarding the pellet. To closely check the peptide concentra-
tion within samples, a reference curve was obtained by analyz-
ing, under the same conditions, different amounts of the pure
compound dissolved inDMSO (the peptide solubility inDMSO
is100 mg/ml). The reference curve was also used to exclude
effects of sample subtraction by nonspecific binding to albumin
or other serum proteins. The experiment was carried out in
duplicate, and the data were reported as residual peptide in
solution (in percentages) versus time.
Inhibition of Flt-1 Phosphorylation and Capillary-like Tube
Formation—These assays were performed as described else-
where (18). In phosphorylation experiments, to induce Flt-1
and KDR receptor activation, 20 ng/ml PlGF and 50 ng/ml
VEGF were used on starved 293-Flt-1 or HUVEC cells. To
detect phosphorylated forms of receptors in Western blot
experiments, anti-pFlt-1 (R&D Systems) at 1:500 dilution and
anti-pKDR (Cell Signaling, Danvers, MA) at 1:1000 dilution
antibodies were used.
Capillary-like tube formation were performed in 24-well cul-
ture plates. At the end of the experiment, the culture medium
was replaced with PBS, and the images were captured with the
inverted microscope Leica DM IRB (Wetzlar, Germany)
equipped with a Leica DC 350 FX camera (original magnifica-
tion10). Images were acquired with Leica FW 4000 software.
Chicken Embryo Chorioallantoic Membrane (CAM) Assay—
Alginate beads (5 l) containing vehicle, 150 ng/embryo of
VEGF-A, or 250 ng/embryo of PlGF with or without peptides
(0.25 and 0.025 nmol/embryo) were prepared as described pre-
viously (32) and placed on top of the CAM of fertilized White
Leghorn chicken eggs at day 11 of incubation (6–8 eggs per
experimental group). After 72 h, new blood vessels converging
toward the implant were counted by two observers in a double-
blind fashion under a stereomicroscope and photographed in
ovo at original magnification 5, using a STEMI SR stereomi-
croscope, equipped with an objective f equal to 100 mm with
adapter ring 475070 (Zeiss, Germany) and a Camedia C-4040
digital camera (Olympus, Melville, NY). Images were acquired
and processed using the Image-Pro Plus software. Differences
among groups were tested by one-way analysis of variance
using the SPSS statistical package (version 12.1, Chicago, IL).
Cornea Neovascularization (CNV)—Single injections (33-
gauge needle) of 0.40, 4.0, or 20 nmol of peptide 4-23-5 and of
only 20 nmol of control peptide in the same volume of DMSO
were carried out in the corneas of BALB/c mice (n  3 each
group). Eyes were harvested 7 days after injection, corneas were
gently isolated, and immunohistochemical staining for endo-
thelial cells was performed. Corneaswere fixed in 100% acetone
for 20 min, washed with PBS, 0.05% Tween 20 for 10 min four
consecutive times, and blocked with 3% BSA in PBS for 48 h.
The corneas were then incubated with fluorescein isothiocya-
nate-coupled monoclonal anti-mouse CD31 antibody (Pharm-
ingen) at 3:1000 and rabbit anti-mouse LYVE-1 antibody
(Abcam, Cambrige, UK) at 3:1000 in 3% BSA PBS solution at
4 °C for 48 h. The corneas were washed as described previously
and incubated in Cy3-conjugated donkey anti-rabbit at 3:1000
in 3% BSA PBS solution for 2 h, after which they were washed
and mounted with an antifading agent (Vectashield, Vector
Laboratories). The corneal flat mounts were visualized with a
fluorescent microscope (Nikon Eclipse TE2000-E) equipped
with Nikon DXM200F camera at original magnification 4.
Images acquisitions were performed with Nikon, ACT-1 soft-
ware, version 2.63. Blood vessels were identified as CD31-pos-
itive and LYVE-1-negative.
RESULTS
Synthesis, Characterization, and Screening of the Combinato-
rial Peptide Library—To increase the molecular surface, the
library was assembled as described previously (28) on a peptide
scaffold composed by a polylysine core (supplemental Fig. S1)
(33). To obtain mixtures, three levels of randomization were
achieved applying the portioning-mixing method (34, 35). The
tetrameric library was synthesized using 29 non-natural amino
acids plus glycine (supplemental Table S1) and was initially
arranged in 30 pools, each identified with theN-terminal build-
ing block. Each pool contained 900 different molecules (302).
The total complexity of the library was instead determined by
the formula 303 27,000 different peptides.
Peptide mixtures were obtained in high yield (about 70%) as
calculated assuming an average molecular mass of 2130 atomic
mass units for each library component and with an average
purity of the crude products85% (as determined on the single
molecules assayed during the last screening round, not shown).
The liquid chromatography-mass spectrometry analyses of
some selected 30-component mixtures showed that the
expected molecules were almost all equally represented and
thatmolecular weights were in very good agreement with those
calculated (not shown). Liquid chromatography-mass spec-
trometry analyses of single peptides also showed very good
Anti-VEGFR-1 PeptideModulates Angiogenesis
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agreement between calculated and experimental molecular
weights (supplemental Table S2).
The screening was carried out by a competition assay,
whereby the displacement of soluble recombinant PlGF from
coated Flt-1 by the peptide pools was evaluated. PlGF was used
in the assay as, among all the VEGF family members, it shows
the highest affinity for Flt-1 (6). The iterative procedure con-
sisted of three screening rounds that led to the selection of
building blocks denoted as 4, 23, and 5 in positions 1, 2, and 3,
respectively (supplemental Table S1). A schematic representa-
tion and the chemical structure of the selected tetrameric trip-
eptide, hereafter named 4-23-5, are reported in Fig. 1. Mono-
mers 4, 23, and 5 refer to the amino acids D-glutamic acid
(D-Glu), S-benzylated L-cysteine, and L-cyclohexylalanine.
The selected peptide was readily resynthesized on a larger
scale and purified by reverse phase HPLC. In the same ELISA
assay, the purified 4-23-5 blocked the interaction of human
PlGF with Flt-1 in a dose-dependent manner, with an IC50 of
about 10 M (Fig. 2A), whereas the control tetrameric peptides
21-1-5 and 4-23-A (supplemental Table S3) did not show any
effect (Fig. 2A).
Inhibitory Properties of the Peptide 4-23-5—Because the
binding mechanism of VEGFs members able to recognize Flt-1
is similar (18, 36–38), we first investigated whether 4-23-5 was
capable to inhibit also the interactions of human VEGF-A and
VEGF-B with Flt-1 receptor. The peptide was able to block in a
dose-dependent fashion the interaction of VEGF-A (Fig. 2B)
and VEGF-B (Fig. 2C) with Flt-1. In the first case, the IC50 was
similar to that observed for PlGF-Flt-1 interaction (about 10
M),whereas forVEGF-B, the IC50was slightly higher (about 18
M). Again, the control tetrameric peptides 21-1-5 and 4-23-A
did not exhibit inhibition. Remarkably, the 4-23-5 peptide also
blocked the interaction between human PlGF/VEGF het-
erodimer with Flt-1 and that of mouse PlGF or VEGF-A with
the corresponding mouse receptor (not shown).
FIGURE 1. Structure of 4-23-5 peptide. A, schematic representation of the
4-23-5 tetrameric tripeptide. L-Cys(Bzl), L-cysteine(S-benzyl); L-Cha, L-cyclo-
hexylalanine. B, chemical structure of the 4-23-5 peptide that has a calculated
MW of 2362.02 atomic mass units.
FIGURE 2. Tetrameric peptide 4-23-5 inhibits the binding of VEGF family
members with Flt-1 receptor. A–C, dose-dependent inhibition of PlGF (A),
VEGF-A (B), and VEGF-B (C) interactionwith Flt-1 exerted by 4-23-5 peptide in
competitive ELISA-basedassays. Tetrameric 4-23-5 (E), 4-23-A (Œ), and21-1-5
(f) peptides were assayed at concentrations ranging between 1.56 and 50.0
M. The results represent the averageof three independent experiments. The
error bars represent the S.D.
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To evaluate the influence of themultimeric structure and the
contribution from single residues on peptide activity, a panel of
analogues was designed, synthesized (supplemental Table S3),
and tested at the single 50 M concentration in the PlGF/Flt-1
competition assay. All sequence (supplemental Fig. S2A) and
structural (supplemental Fig. S2B) variants tested were ineffec-
tive or exhibited only a slight activity when compared with the
parent 4-23-5 peptide used at 12.5 M. These outcomes indi-
cate that both the sequence and themultimeric structure of the
4-23-5 peptide are required for its inhibitory properties.
Binding Properties of the Peptide 4-23-5—The ability of
selected peptide to inhibit the interaction of all three VEGF
family members with Flt-1 receptor suggested that it seemingly
interacts with the receptor. To validate this hypothesis, 4-23-5
or control peptides were coated on microtiter plates, and the
binding of soluble growth factors or chimeric recombinant
Fc/Flt-1 receptors was assessed by ELISA assays. Remarkably,
VEGF-A and PlGF did not bind the immobilized peptide (not
shown), whereas both human and mouse Flt-1 specifically
interacted with the synthetic ligand (Fig. 3A) in a dose-depend-
ent manner (supplemental Fig. S3). Moreover, PlGF and
VEGF-A were both able to inhibit in a dose-dependent manner
the binding of Flt-1 to coated 4-23-5 peptide, showing a 50%
inhibitionwhen used at 10-foldmolar excess over Flt-1 concen-
tration (Fig. 3B). Importantly, the peptide failed to bind KDR
and Flk-1 receptors (Fig. 3C), demonstrating a strong selectivity
for the high affinity receptor.
Stability and Neutralizing Properties of Peptide 4-23-5—Be-
fore starting cell-based assays, we verified the stability of 4-23-5
in serumover time.This tetrameric ligand, composed by unnat-
ural amino acids, was essentially fully stable in 10% FBS for 7
days (168 h) (Fig. 4A). This experiment also proved that, under
these conditions, the peptide did not bind serum proteins as no
peptide subtraction by the precipitation of serum proteins per-
formed before the HPLC analysis was observed (see “Experi-
mental Procedures”).
The neutralizing activity of 4-23-5 peptide was initially eval-
uated in receptor phosphorylation assays. The peptide was able
to reduce in a dose-dependent manner PlGF- and VEGF-in-
duced phosphorylation of human Flt-1 in a cell line (293-Flt-1)
(18) stably overexpressing the receptor (Fig. 4, B and C, respec-
tively). Notably, when used at 4.0M, the peptide prevented the
phosphorylation of more than 50%. At 20 M, the efficacy
increased and was similar to that obtained with a neutralizing
anti-PlGFmAb (16D3, Thrombogenics, Leuven, Belgium) (Fig.
4B) or with neutralizing anti-VEGF antibodies (R&D Systems)
(Fig. 4C) used at about 3 nM. The control peptide 21-1-5 used at
20 M was ineffective in both experiments (Fig. 4, B and C). As
expected on the basis of the ELISA data, the peptide was unable
to interfere with the VEGF-A-induced KDR phosphorylation
on HUVEC when used at 20 M (Fig. 4D), confirming its high
selectivity for Flt-1 over the lower affinity receptor (Fig. 3C).
Anti-angiogenic Activity of the 4-23-5 Peptide—The anti-an-
giogenic activity of the selected peptide was first assessed by
testing its capability to suppress the induction of capillary-like
tube formation (CTF), stimulated by PlGF or VEGF-A, of
human primary endothelial cells (HUVEC) grown onMatrigel.
HUVECs stimulated by PlGF (Fig. 5, A–G) or VEGF-A (Fig. 5,
H–N) were able to generate structures similar to capillaries (Fig.
5,A andH). As shown in Fig. 5,B and I, the suppression of PlGF-
and VEGF-A-induced CTF by 4-23-5 was virtually complete at
20 M, whereas the control peptides 4-23-A and 21-1-5 were
totally inactive even at 50 M (Fig. 5, C and J and D and K,
respectively). 4-23-5 was also tested at 4.0, 0.80, and 0.16 M
(Fig. 5, E, L, F, andM andG andN, respectively), showing again
a complete inhibition at 4.0 M. At 0.80 M, CTF was only
FIGURE 3. Tetrameric peptide 4-23-5 binds specifically to Flt-1 receptor.
The binding properties of selected peptide were assessed by ELISA-based
assays. A, binding of human (black bar) or mouse (gray bar) Flt-1 receptors
(250 pM) to 4-23-5 peptide coated on a microtiter plate at 20 M. The two
receptors failed to bind to three control peptides: 4-23-5 dimer, 4-23-A, and
21-1-5 coated at the same concentration. B, dose-dependent inhibition of
Flt-1 (125 pM) interactionwith coated 4-23-5 peptide (20M) exerted by PlGF
(E) and VEGF-A (Œ). Soluble growth factors were assayed at concentrations
ranging from 0.05 to 6.25 nM. C, dose-dependent interaction of human and
mouse Flt-1 (hFlt-1 andmFlt-1) assayed at 125pM (black bar) and 250pM, (gray
bar) with 4-23-5 peptide coated at 20 M. VEGFRs-2 (human KDR (hKDR) and
mouse Flk-1 (mFlk-1)) failed to bind 4-23-5 peptide in the same conditions.
The results represent the average of three independent experiments. The
error bars represent the S.D.
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partially suppressed, whereas at the lowest concentration, the
inhibition activity was essentially lost.
The anti-angiogenic activity of the peptide was confirmed in
the in vivo model of the CAM assay (32). Alginate beads
adsorbed with VEGF-A or PlGF alone or added with peptides
were implanted on the top of 11-day-old chick embryo CAMs.
VEGF-A (Fig. 6A) and PlGF (Fig. 6B) exerted a potent angio-
genic response when compared with beads adsorbed with vehi-
cle or peptides alone (Fig. 6A).
The addition of 4-23-5 peptide significantly inhibited the
angiogenic response stimulated by either PlGF or VEGF-A in a
dose-dependent manner in all the embryos tested. In contrast,
no inhibition was elicited by the control peptide 21-1-5, except
for a partial inhibition observed only in 2 out of the 6 embryos
stimulated with VEGF-A and treated with 0.25 nmol of the
control peptide (Fig. 6, and for representative pictures, see sup-
plemental Fig. S4).
Peptide 4-23-5 Stimulates Corneal Neoangiogenesis—The
molecular mechanism responsible for corneal avascularity
has been recently elucidated (26). Corneal avascularity is
maintained by the abundant expression of sFlt-1 and by the
concomitant absence of full-length Flt-1. Indeed, although it
is avascular, the cornea expresses VEGF-A, whose activity is
prevented by sFlt-1. These findings make the cornea an ideal
platform to assess the in vivo activity of neutralizing anti-
Flt-1 molecules because, as reported previously, injection in
the cornea of molecules able to displace VEGF from sFlt-1,
such as anti-Flt-1 antibodies or PlGF, should induce sponta-
neous CNV (26). The injection of 20 nmol of peptide
potently induced CNV (Fig. 7, C and G). The effect was also
dose-dependent because injection of 4.0 nmol (Fig. 7, B and
F) or 0.40 nmol (Fig. 7, A and E) still produced clearly visible
effects, although to a reduced extent. Conversely, the injec-
tion of 20 nmol of control peptide 21-1-5 was unable to
induce CNV (Fig. 7, D and H). Interestingly, the immunoflu-
orescence analysis of cornea reported in Fig. 7G showed that
after injection of the highest dosage of peptide, the forma-
tion of lymphatic vessels (red LYVE-1-positive vessels) was
observable. Of utmost importance, a single injection of
4-23-5 produced a sustained effect detectable up to 7 days, in
agreement with the high peptide stability observed in vitro
(Fig. 4A).
DISCUSSION
Current strategies to block receptor tyrosine kinase activity
are based on neutralization of natural ligands interaction or on
inhibition of tyrosine kinase activity. Due to the high specificity
and affinity, mAbs represent the primary approach for ligand
neutralization. However, synthetic molecules still offer numer-
ous advantages over biotherapeutics as they can be more easily
analyses. Anti-phospho-Flt-1 (pFlt-1) or anti-phospho-KDR (pKDR) antibodies
were used to detect the level of receptor phosphorylation, whereas anti-Flt-1
(Flt-1) or anti-KDR (KDR) antibodieswere used for normalization. The values of
densitometry analyses, performed using ImageQuant 5.2 software (GE
Healthcare) are shown. Values (in percentages)were calculated as the ratio of
degree of receptor phosphorylation with respect to the total receptor
amounts. The value of 100 has been arbitrarily assigned to PlGF- or VEGF-
induced samples.
FIGURE 4. Stability and neutralizing properties of peptide 4-23-5. A, the
resistance to enzyme degradation of the selected peptide was assessed by
incubation in 10% fetal calf serum for 168 h. At time 0, after every hour within
the first 12 h, and at 24, 72, 120, and 168 h, three aliquots were removed,
centrifuged to remove proteins, and analyzed by HPLC (10l, 1g). Residual
peptide quantity, expressed as the percentage of the initial amount versus
time, was plotted. The results represent the average of three independent
experiments. The error bars represent the S.D. The ability of selected peptide
to inhibit the VEGFRs activation exerted by PlGF andVEGF-Awas evaluated in
receptor phosphorylation assays (B–D). Starved 293-hFlt1 cells were stimu-
lated with 20 ng/ml PlGF (B) or 50 ng/ml of VEGF-A (C) for 10 min, in the
presence or absence of active and control peptides. As controls, neutralizing
anti-PlGF or anti-VEGF antibodies were used. Similarly, starved HUVECs were
stimulated with VEGF-A (D). 100 g of cell lysate were used for Western blot
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and cheaply produced, aremore stable, and are generally free of
contaminants of biological origin. Furthermore, they offer
more opportunity for delivery.
In this perspective, we undertook a screening of combinato-
rial peptide libraries to search for antagonists of the VEGF high
affinity receptor, which controls a variety of biological func-
tions associated with pathological conditions (7). We report
here the identification of a synthetic tetrameric tripeptide that
binds to Flt-1 and prevents its interaction with all members of
VEGF family able to recognize it (Fig. 2). The peptide has been
selected from a library made with unnatural amino acids and
screened by a competitive ELISA-based assay. Tetrameric
structures based on branched polylysine were chosen to assem-
ble random sequences as they reportedly increase the avidity of
peptides for their targets (39) and, at the same time, enhance
FIGURE 5.Tetrameric tripeptide 4-23-5 inhibits capillary-like tube forma-
tion induced by PlGF or VEGF-A. A–N, representative pictures of capillary-
like tube formation stimulated with 100 ng/ml PlGF (A–G) or VEGF-A (H–N) in
thepresence or absence of active and control peptides. PlGF (A) or VEGF-A (H)
in endothelial basal medium (EBM-2) was able to stimulate the formation of
structure similar to capillaries. 4-23-5 peptide at 20M completely prevented
CTF induced by PlGF (B) or VEGF-A (I), whereas control peptides 4-23-A (C and
J) and 21-1-5 (D and K) at 50M failed to block CTF. Tetrameric peptide 4-23-5
was still able to fully block CTF stimulated by both PlGF and VEGF-A at 4.0M
(E and L). At 0.80 M (F and M), a partial inhibitory effect was still present,
whereas at 0.16 M (G and N), peptide lost the capability to inhibit CTF (orig-
inal magnification10).
FIGURE 6. Tetrameric tripeptide 4-23-5 inhibits in vivo neovessels forma-
tion stimulated by VEGF-A or PlGF in CAM assay. A and B, alginate beads
containing150ng/embryoofVEGF-A (A) or 250ng/embryoofPlGF (B),withor
without peptides, vehicle, or peptides alone, were placed on top of the CAM
of fertilized White Leghorn chicken eggs at day 11 of incubation (6–8 eggs
per experimental group). After 72 h, new blood vessels converging toward
the implantwere countedby twoobservers in a double-blind fashionunder a
stereomicroscope. Black bars, VEGF-A or PlGF; light gray bars, factors plus 0.25
nmol of peptides or peptides alone; dark gray bars, factors plus 0.025 nmol of
peptide;white bars, vehicle. 4-23-5peptide significantly inhibitedeither PlGF-
induced or VEGF-A-induced angiogenesis in a dose-dependentmanner in all
the embryos tested. No inhibition was detected with the control peptide
21-1-5, except for a partial inhibition observed only in 2 out of the 6 embryos
stimulated with VEGF-A and treated with 0.25 nmol of the control peptide.
The error bars represent the S.D. *, p  0.005 versus VEGF-A; #, p  0.0001
versus VEGF-A; ¶, p 0.05 versus VEGF-A or PlGF; §, p 0.005 versus PlGF.
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the resistance to degradation by proteolytic enzymes (30). The
use of unnatural amino acids further improves the stability of
the resulting molecules, and indeed, the selected ligand shows
an outstanding resistance in 10% serum (Fig. 4A) when com-
paredwith other recently reported anti-Flt-1 peptides (40–42).
This property can be of particular interest in view of potential
therapeutic applications.
The 4-23-5 peptide, despite the apparent low receptor affin-
ity (around 10 M), displays a high binding specificity for
VEGFR-1, as demonstrated both in ELISA (Fig. 3C) and in
receptor phosphorylation (Fig. 4, B–D) assays. Despite the
sequence and structural similarity between the two VEGF
receptors, the selected peptide appears incapable to interact
with VEGFR-2. The anti-angiogenic activity of the 4-23-5 pep-
tide has been demonstrated using two of the most common
angiogenic assays, the CTF and the CAM neoangiogenesis
assays and, in both experimental approaches, it is able to pre-
vent the pro-angiogenic activity stimulated by PlGF or
VEGF-A.
Notably, suppression of CTF stimulated by PlGF or VEGF
(Fig. 5) demonstrates that the neutralization of ligand binding
to Flt-1, and thus the block of the downstream receptor signal-
ing, is sufficient alone to prevent all the biological events inte-
gral to the CTF process, such as cell proliferation, migration,
and differentiation. In the same manner, the 4-23-5 peptide is
capable to strongly inhibit in a dose-dependent way PlGF- and
VEGF-induced CAM neovascularization (Fig. 6 and supple-
mental Fig. S4). The inhibition of CTF and neoangiogenesis of
CAM induced by PlGF was expected, due to the ability of PlGF
to exclusively bind to Flt-1 receptor.
Remarkably, the observed complete blocking of VEGF-A-
induced CTF together with the strong inhibition of VEGF-in-
duced angiogenesis in the CAM assay exerted by 4-23-5 indi-
cates that, despite the presence of both VEGFRs, in vitro and in
vivo angiogenic response toVEGF stimulation can be abrogated
by selective inhibition of the high affinity receptor alone (7, 40,
41). This result is supported by very recent data that demon-
strated how the activation of Flt-1 is crucial for a correct stim-
ulation of ECs by VEGF (19). Permanent inhibition of Flt-1
expression by RNA interference (using small interfering RNA)
inhibited VEGF-A-induced HUVEC proliferation and CTF,
with an extent higher than that obtained with permanent inhi-
bition of KDR expression. Moreover, the deletion of Flt-1
induced a reduction of cell lifespan and an increase of cell
senescence via p53/p21-dependent pathways, whereas that of
KDR inhibited cell survival. In addition, it has been demon-
strated that in vivo, the dosage of Flt-1 is crucial because recov-
ery from hind limb ischemia was impaired in heterozygous flt-
1/ mice. Interestingly, although it was previously reported
that Flt-1 is able to interact with phosphatidylinositol 3-kinase
(43), in both in vitro and in vivo approaches, the authors found
that the total or the partial absence of Flt-1 leads to an increase
of Akt activation by VEGF via VEGFR-2. The ability of VEGF to
stimulate phosphatidylinositol 3/Akt pathway and cell survival
via VEGFR-2 was already known (44). Interestingly the angio-
genic impairment observed in flt-1/ mice was annulled in
double heterozygous flt-1/ akt/ mice, in agreement with
previous findings demonstrating that akt/ mice showed an
augmented angiogenic response (45).
The specific and dose-dependent block of Flt-1 by 4-23-5
peptide may thus mimic the effect observed with small inter-
fering RNA and was sufficient to inhibit both VEGF-depend-
ent angiogenesis in CTF (Fig. 5) and neovascularization of
CAM (Fig. 6). The strong effect we observe in the CAM assay
after 72 h from the stimulus was probably due both to cell
proliferation inhibition and to cell lifespan reduction, facili-
tated by the high stability of the peptide that allows a sus-
tained inhibitory effect over the time. It should be consid-
ered also that the block of Flt-1 activation prevents possible
cross-talk between the two receptors (46, 47) other than
VEGF-induced receptors heterodimerization, whose role
has not yet been fully elucidated.
FIGURE 7. Tetrameric tripeptide 4-23-5 stimulates corneal neovascular-
ization. A total of 0.4 (A and E), 4.0 (B and F), or 20.0 (C and G) nmol of 4-23-5
peptide and 20.0 nmol of control peptide 21-1-5 (D and H), in the same vol-
ume of DMSO, were injected in the corneas of BALB/c mice. After 7 days,
corneas were photographed (A–D) and then harvested and flat-mounted. In
A, new vessels are indicated with arrows. New vessels were immunostained
(E–H) using anti-mouse CD31 antibodies (green) and anti-mouse-LYVE-1 anti-
bodies (red). The areas corresponding to cornea have been indicated with a
white circle. Blood vessels were defined as CD31-positive and LYVE-1-nega-
tive (original magnification4).
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The dose-dependent stimulation of CNVobserved after pep-
tide injection (Fig. 7) was similar to that previously obtained
with neutralizing anti-Flt-1 antibodies or with small interfering
RNA inhibition of sFlt-1 (26), suggesting that 4-23-5 peptide is
able to displace the VEGF-A-sFlt-1 complex present in the cor-
nea in physiological conditions, increasing the availability of
VEGF-A for the stimulation of CNV. The similarity of the
effects obtained with the specific anti Flt-1 reagents previously
utilized and those induced with 4-23-5 peptide strongly sug-
gests, as already demonstrated in ELISA and receptor phospho-
rylation assays, that the selected peptide has an elevated selec-
tivity for Flt-1 also in vivo. Moreover, the absence of full-length
Flt-1 receptor in the cornea suggests that VEGF-VEGFR2 inter-
action is crucial for theCNV, again supporting the view that the
4-23-5 peptide does not recognize VEGFR-2. This was also cor-
roborated by the observation that at the highest peptide con-
centration injected in the cornea, the formation of new lym-
phatic vessels was evident (Fig. 7G), a result consistent with
recent data on the ability of VEGF-A to also stimulate lym-
phangiogenesis and with findings indicating that the VEGF-
VEGFR-2 interaction is crucial for this process (48). However,
due to the peculiarity of this compartment, we cannot rule out
that the observed CNV might also be due to other additional
unknown or not well characterized mechanisms, such as pre-
venting the ability of sFlt-1 to inhibit the activity of VEGF
receptors by dimerization with their membrane bound forms
(25).
Collectively, our results suggest that the peptide 4-23-5 is a
new specific anti-Flt-1 compound with potential applications
for molecular therapeutic approaches of pathologies in which
angiogenesis and inflammation represent critical events.
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